United States ex rel. Steven May v. Purdue Pharma L.P.

811 F.3d 636, 2016 U.S. App. LEXIS 1497, 2016 WL 362250
CourtCourt of Appeals for the Fourth Circuit
DecidedJanuary 29, 2016
Docket14-2299
StatusPublished
Cited by7 cases

This text of 811 F.3d 636 (United States ex rel. Steven May v. Purdue Pharma L.P.) is published on Counsel Stack Legal Research, covering Court of Appeals for the Fourth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
United States ex rel. Steven May v. Purdue Pharma L.P., 811 F.3d 636, 2016 U.S. App. LEXIS 1497, 2016 WL 362250 (4th Cir. 2016).

Opinion

Affirmed by published opinion. Judge DIAZ wrote the opinion, in which Chief Judge TRAXLER and Judge AGEE joined.

DIAZ, Circuit Judge:

Steven May and Angela Radcliffe (the “Relators”) appeal the district court’s dismissal of their qui tam action under the False Claims Act (“FCA”), 31 U.S.C. § 3729 et seq. They contend that the district court incorrectly concluded that (1) the pre-2010 version of the FCA’s “public disclosure bar,” 31 U.S.C. § 3730(e)(4) (2009), divested the court of subject matter jurisdiction; and, alternatively, (2) the Re-lators failed to plead fraud in accordance with Federal Rule of Civil Procedure 9(b). We agree that the public disclosure bar left the district court without jurisdiction over the Relators’ FCA claims; therefore, we do not reach the court’s alternative ground for dismissal. Accordingly, we affirm.

I.

The FCA allegations at issue have enjoyed a long though not particularly fruitful life, having reached this court now for the third time. Ten years ago, Mark Radcliffe — a former district sales manager for Purdue Pharma (“Purdue”) — filed a qui tam action under the FCA against Purdue. United States ex rel. Radcliffe v. Purdue Pharma L.P., 600 F.3d 319, 321-22 (4th Cir.2010). He alleged a fraudulent scheme whereby Purdue marketed the pain medication OxyContin as having a falsely inflated 2:1 equianalgesic ratio — which is a measure of a painkiller’s potency — as compared to one of Purdue’s older pain drugs, MS Contin. Id. at 321. By overstating the ratio, Radcliffe claimed, Purdue deceived physicians into prescribing — and the federal government into paying for— OxyContin instead of less costly MS Con-tin. Id. at 321-22 & n. 3. In 2010, we held that Radcliffe’s qui tam action must be dismissed based on a release he executed upon accepting a severance package from Purdue after it restructured its workforce. Id. at 322 & n. 2, 324.

Less than two months after the Supreme Court denied Radcliffe’s petition for certiorari, United States ex rel. Radcliffe v. Purdue Pharma, L.P., 562 U.S. 977, 131 S.Ct. 477, 178 L.Ed.2d 315 (2010), his wife Angela decided to “take up ... the baton” and file the qui tam action against Purdue now before the court. J.A. 434. Joining her as a relator is Steven May, a former Purdue employee who worked under Mr. Radcliffe. One of their attorneys is Mark Hurt, who was Mr. Radcliffe’s counsel throughout his qui tam action.

The allegations in the Relators’ lawsuit are “nearly identical to” those pursued by Mr. Radcliffe. United States ex rel. May v. Purdue Pharma L.P., 737 F.3d 908, 911 (4th Cir.2013), cert. denied, — U.S. -, 135 S.Ct. 2376, 192 L.Ed.2d 177 (2015). While the district court found that the Relators did not base their allegations on a personal review of the documents filed in Mr. Radcliffe’s suit, the court concluded that their “contribution to the case was essentially to provide plaintiffs’ names not associated with the release that barred Mr. Radcliffe’s suit.” J.A. 1323-24. The facts of the fraudulent scheme alleged in this action come from Mr. Hurt, who “simply used his own knowledge developed during [Mr. Radcliffe’s suit] and the documents provided by Mr. Radcliffe ... to draft the pleadings here.” J.A. 1323.

*639 The district court dismissed the Rela-tors’ suit on res judicata grounds, giving preclusive effect to Mr. Radcliffe’s qui tam action. United States ex rel. May v. Purdue Pharma L.P., No. 10-cv-01423, 2012 WL 4056720, at *4-5 (S.D.W.Va. Sept. 14, 2012). We vacated that judgment, holding that Mr. Radcliffe’s release “was personal to him” and “could not serve as a defense to any claims that the Relators (or other non-signatories) might assert against Purdue.” May, 737 F.3d at 913-14, 920. And while Purdue argued that we could affirm the district court’s dismissal on the alternative theory that the public disclosure bar precluded the Relators’ action, we explained that ruling on that issue would be premature, as the district court had not made the requisite jurisdictional findings of fact. Id. at 919-20.

On remand, the district court dismissed the Relators’ amended complaint, holding that their allegations were based on the claims from Mr. Radcliffe’s suit and therefore the public disclosure bar stripped the court of subject matter jurisdiction. In the alternative, the court (1) held that the Relators failed to plead fraud with particularity under Rule 9(b), and (2) denied the Relators leave to further amend their complaint. 1

This appeal followed.

II.

A.

The FCA provides a cause of action “against anyone who ‘knowingly presents’ to the government ‘a false or fraudulent claim for payment or approval.’ ” United States ex rel. Owens v. First Kuwaiti Gen. Trading & Contracting Co., 612 F.3d 724, 728 (4th Cir.2010) (quoting § 3729(a)(1)). “In adopting the FCA, ‘the objective of Congress was broadly to protect the funds and property of the government.’ ” Id. (quoting Rainwater v. United States, 356 U.S. 590, 592, 78 S.Ct. 946, 2 L.Ed.2d 996 (1958)).

To fulfill this objective, the FCA in certain circumstances permits qui tam actions, which “provide cash bounties ... to private citizens who successfully bring suit against those who defraud the federal government.” United States ex rel. Springfield Terminal Ry. Co. v. Quinn, 14 F.3d 645, 649 (D.C.Cir.1994). One barrier to bringing a qui tam action under the FCA, however, is its “public disclosure bar.” While Congress amended the public disclosure bar in 2010, we held that in the instant case, which involves allegations between 1996 and 2005, the pre-2010 version of the bar governs. May, 737 F.3d at 914-18. It provides:

No court shall have jurisdiction over an action under this section based upon the public disclosure of allegations or transactions in a criminal, civil, or administrative hearing ... unless the action is brought by the Attorney General or the person bringing the action is an original source of the information.

31 U.S.C. § 3730(e)(4)(A) (2009).

We interpret the phrase “based upon” in the pre-2010 public disclosure bar differently than our sister circuits. United States ex rel. Ondis v.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Fitzer v. Allergan, Inc.
D. Maryland, 2024
United States ex rel. Vitale v. Mimedx Grp., Inc.
381 F. Supp. 3d 647 (D. South Carolina, 2019)
Barnes v. United States
353 F. Supp. 3d 582 (N.D. Texas, 2019)
United States ex rel. Brown v. BankUnited Trust 2005-1
235 F. Supp. 3d 1343 (S.D. Florida, 2017)
Joyce Whitaker v. Milwaukee County, Wisconsin
772 F.3d 802 (Seventh Circuit, 2014)

Cite This Page — Counsel Stack

Bluebook (online)
811 F.3d 636, 2016 U.S. App. LEXIS 1497, 2016 WL 362250, Counsel Stack Legal Research, https://law.counselstack.com/opinion/united-states-ex-rel-steven-may-v-purdue-pharma-lp-ca4-2016.